This acquisition confirms Biotica’s position in polyketide therapeutics, a biologically rich and broadly applicable class of drugs.

The new IP  significantly enhances Biotica’s capabilities in manufacturing development through use of heterologous expression systems, with potential for reducing cost of goods and development time.

In addition to this IP acquisition, Biotica has extended its platform by building a proprietary library of naturally-occurring polyketides. These compounds are uniquely able to address major clinical unmet need, having inherent biological activity, often against targets that are difficult to modulate using traditional synthetic small molecules.

With its growing library and expanded technology platform, Biotica is uniquely positioned to identify, optimise and manufacture polyketide therapeutics.

Edward Hodgkin, CEO of Biotica, said: “Consolidating the Kosan IP with Biotica’s is a fundamental strategic move for us. We believe we are now the only company able to exploit the enormous potential of the polyketide opportunity.”

Will this acquisition benefit Biotica?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.